Boji Medical details shareholder returns, revises governance amid profit dip

Boji Medical & Biotechnological has released its 2026-2028 shareholder return plan, prioritizing continuous and stable dividends while balancing sustainable development. The plan details cash dividend payout ratios ranging from 15% to 80% based on the company's development stage and capital expenditure needs. Concurrently, the company announced its 2025 half-year financial results, reporting revenue of CNY 361,448,457.00 and a net profit of CNY 15,569,864.27, a decrease of 48.33% year-on-year, partly attributed to a provision for asset impairment and credit losses totaling CNY 13,366,516.57.

The board also approved several governance overhauls, including revisions to the articles of association to reflect changes in share capital and regulatory requirements, transferring supervisory board functions to the audit committee, and updating multiple internal management systems. These changes align with new company law and stock exchange guidelines, aiming to enhance corporate governance and operational efficiency. The company also confirmed the cancellation of 12,000 restricted shares from the 2023 incentive plan due to an employee resignation. The board's decisions are subject to shareholder approval at the upcoming extraordinary general meeting on September 12, 2025.